CR20110612A - Metodo para la preparacion de hidrocloruro de nalmefeno - Google Patents

Metodo para la preparacion de hidrocloruro de nalmefeno

Info

Publication number
CR20110612A
CR20110612A CR20110612A CR20110612A CR20110612A CR 20110612 A CR20110612 A CR 20110612A CR 20110612 A CR20110612 A CR 20110612A CR 20110612 A CR20110612 A CR 20110612A CR 20110612 A CR20110612 A CR 20110612A
Authority
CR
Costa Rica
Prior art keywords
nalmefen
hydrocloride
preparation
nalmefene hydrochloride
naltrexone
Prior art date
Application number
CR20110612A
Other languages
English (en)
Inventor
Faveri Carla De
Mauro Casarin
Michele Brusegan
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43222172&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20110612(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of CR20110612A publication Critical patent/CR20110612A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un método para producir hidrocloruro de nalmefeno a partir de naltrexona, el cual está particularmente bien adaptado para aplicación a escala industrial y se ha averiguado que es eficiente para ofrecer rendimiento y proporcionar la sal hidrocloruro de nalmefeno de alta pureza.
CR20110612A 2009-05-25 2011-11-22 Metodo para la preparacion de hidrocloruro de nalmefeno CR20110612A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200900650 2009-05-25
US18102209P 2009-05-26 2009-05-26

Publications (1)

Publication Number Publication Date
CR20110612A true CR20110612A (es) 2012-02-22

Family

ID=43222172

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110612A CR20110612A (es) 2009-05-25 2011-11-22 Metodo para la preparacion de hidrocloruro de nalmefeno

Country Status (35)

Country Link
US (1) US8598352B2 (es)
EP (1) EP2435439B8 (es)
JP (1) JP5794980B2 (es)
KR (1) KR101716522B1 (es)
CN (1) CN102459276B (es)
AR (1) AR076891A1 (es)
AU (1) AU2010252392B2 (es)
BR (1) BRPI1010975B1 (es)
CA (1) CA2763093C (es)
CL (1) CL2011002974A1 (es)
CO (1) CO6470832A2 (es)
CR (1) CR20110612A (es)
DK (1) DK2435439T3 (es)
DO (1) DOP2011000362A (es)
EA (1) EA019331B1 (es)
ES (1) ES2564006T3 (es)
GE (1) GEP20146190B (es)
HR (1) HRP20160110T1 (es)
HU (1) HUE026892T2 (es)
IL (1) IL216422A (es)
MA (1) MA33368B1 (es)
ME (1) ME02622B (es)
MX (1) MX2011012502A (es)
MY (1) MY158251A (es)
NZ (1) NZ596988A (es)
PL (1) PL2435439T3 (es)
RS (1) RS54599B1 (es)
SG (1) SG176205A1 (es)
SI (1) SI2435439T1 (es)
SM (1) SMT201600061B (es)
TN (1) TN2011000590A1 (es)
TW (1) TWI469985B (es)
UA (1) UA106752C2 (es)
WO (1) WO2010136039A1 (es)
ZA (1) ZA201108659B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011263417B2 (en) 2010-06-11 2014-03-27 Rhodes Technologies Transition metal-catalyzed processes for the preparation of N-allyl compounds and use thereof
SI2635586T1 (sl) 2010-11-05 2017-07-31 H. Lundbeck A/S Metoda za izdelavo naltreksona
CN103012416B (zh) * 2011-09-28 2015-07-01 辽宁海思科制药有限公司 一种盐酸纳美芬的制备方法
TWI560170B (en) * 2011-12-06 2016-12-01 Lundbeck & Co As H Process for recovery of nalmefene hydrochloride
CN102584840A (zh) * 2011-12-28 2012-07-18 南京优科生物医药有限公司 一种制备纳美芬化合物的方法
AR090916A1 (es) 2012-05-03 2014-12-17 Lundbeck & Co As H Metodo para la fabricacion de naltrexona
US20140005216A1 (en) 2012-06-27 2014-01-02 H. Lundbeck A/S Nalmefene for reduction of alcohol consumption in specific target populations
CN103204859B (zh) * 2013-04-25 2015-12-02 四川海思科制药有限公司 一种盐酸纳美芬化合物及其制备方法
AR096851A1 (es) 2013-07-11 2016-02-03 H Lundbeck As Sales que no forman hidratos ni solvatos de nalmefeno
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
WO2015163486A1 (en) 2014-04-22 2015-10-29 Otsuka Pharmaceutical Co., Ltd. Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
CN104513251A (zh) * 2014-11-28 2015-04-15 安徽悦康凯悦制药有限公司 一种盐酸纳美芬的制备方法
US9757372B2 (en) * 2015-03-25 2017-09-12 Taiwanj Pharmaceuticals Co., Ltd. Toll-like receptor 4 antagonists and use in autoimmune liver diseases
RU2712232C1 (ru) * 2018-10-05 2020-01-27 Федеральное государственное унитарное предприятие "Научно-исследовательский институт гигиены, профпатологии и экологии человека" Федерального медико-биологического агентства Улучшенный способ получения налмефена из налтрексона
US10927121B1 (en) 2019-12-20 2021-02-23 Southwest Research Institute Technologies for removing residual solvent from nalmefene hydrochloride and producing crystalline nalmefene hydrochloride monohydrate, monosolvate, or crystalline nalmefene hydrochloride dihydrate
WO2022094470A1 (en) 2020-11-02 2022-05-05 Rhodes Technologies Process for purifying noroxymorphone
WO2022165040A1 (en) * 2021-01-28 2022-08-04 Rhodes Technologies Process for crystallizing nalmefene hydrochloride
CN117986261B (zh) * 2024-04-02 2024-06-18 成都瑞尔医药科技有限公司 一种盐酸纳美芬母液的回收套用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4341764A (en) 1980-03-05 1982-07-27 Cutter Laboratories, Inc. Method of preparing fibronectin and antihemophilic factor
US4322426A (en) * 1980-04-28 1982-03-30 E. I. Du Pont De Nemours And Company 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists
US4535157A (en) * 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4751307A (en) 1985-01-17 1988-06-14 Mallinckrodt, Inc. Wittig-reaction processes
US4880813A (en) * 1988-07-22 1989-11-14 Baker Cummins Pharmaceuticals, Inc. Method of treatment for allergic rhinitis
US7687646B2 (en) 2006-03-28 2010-03-30 Azad Pharmaceutical Ingredients, Ag Polymorphic forms of olopatadine hydrochloride and methods for producing olopatadine and salts thereof
GB2447013A (en) * 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition containing buprenorphone and nalmefene

Also Published As

Publication number Publication date
JP5794980B2 (ja) 2015-10-14
CA2763093C (en) 2017-03-07
TW201043634A (en) 2010-12-16
CL2011002974A1 (es) 2012-04-13
ZA201108659B (en) 2013-02-27
EP2435439B8 (en) 2016-05-18
US8598352B2 (en) 2013-12-03
HUE026892T2 (en) 2016-07-28
NZ596988A (en) 2013-03-28
UA106752C2 (uk) 2014-10-10
TN2011000590A1 (en) 2013-05-24
ES2564006T3 (es) 2016-03-17
JP2012527489A (ja) 2012-11-08
US20120123123A1 (en) 2012-05-17
BRPI1010975A2 (pt) 2015-10-20
IL216422A (en) 2015-06-30
IL216422A0 (en) 2012-02-29
WO2010136039A1 (en) 2010-12-02
KR101716522B1 (ko) 2017-03-14
BRPI1010975B1 (pt) 2021-08-24
ME02622B (me) 2017-06-20
CN102459276B (zh) 2016-09-21
PL2435439T3 (pl) 2016-05-31
SMT201600061B (it) 2016-07-01
TWI469985B (zh) 2015-01-21
AU2010252392A1 (en) 2012-01-12
DOP2011000362A (es) 2012-07-15
MA33368B1 (fr) 2012-06-01
AR076891A1 (es) 2011-07-13
DK2435439T3 (en) 2016-02-29
SG176205A1 (en) 2011-12-29
EA019331B1 (ru) 2014-02-28
RS54599B1 (en) 2016-08-31
EP2435439B1 (en) 2016-01-06
CA2763093A1 (en) 2010-12-02
GEP20146190B (en) 2014-11-10
KR20120023704A (ko) 2012-03-13
HRP20160110T1 (hr) 2016-03-11
AU2010252392B2 (en) 2014-10-23
MX2011012502A (es) 2011-12-12
SI2435439T1 (sl) 2016-06-30
EP2435439A1 (en) 2012-04-04
CN102459276A (zh) 2012-05-16
EA201171461A1 (ru) 2012-05-30
MY158251A (en) 2016-09-30
CO6470832A2 (es) 2012-06-29

Similar Documents

Publication Publication Date Title
CR20110612A (es) Metodo para la preparacion de hidrocloruro de nalmefeno
TN2013000411A1 (en) Branched 3-phenylpropionic acid derivatives and the use thereof
CL2011000797A1 (es) Metodo para producir anticuerpos a partir de celulas plasmaticas que comprende el cultivo de celulas plasmaticas en cantidades limitadas.
BRPI0812362A2 (pt) Métodos para produção de hidrogênio a partir de borano de am^nia
EP2248906A4 (en) PROCESS FOR THE PREPARATION OF L-AMINO ACID
EP2113570A4 (en) PROCESS FOR PRODUCTION OF L-AMINO ACID
IT1395068B1 (it) Processo per la produzione di galatto-oligosaccaridi ultrapuri
MX2012007717A (es) Cepas y metodo para la produccion de metionina.
UA111142C2 (uk) Одержання заміщених похідних 2-фторакрилової кислоти
BR112012019006A2 (pt) processo para a produção de ácidos carboxilícos com 1 a 3 átomos de carbono a partir de fontes renováveis
PL2129786T3 (pl) Sposób wytwarzania L-aminokwasów z zastosowaniem szczepów z rodziny Enterobacteriaceae
EP2025759A4 (en) PROCESS FOR PREPARING HYDROXYCARBOXYLIC ACID BY IMPROVING COENZYME SYNTHESIS
BR112012004482A2 (pt) "método para produzir um l-aminoácido"
EA201300647A1 (ru) Оптимизированный синтез чистых неполиморфных кристаллических жёлчных кислот с заданным размером частиц
MX2010003213A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
UA106886C2 (uk) Спосіб одержання 1-бензил-3-гідроксиметил-1h-індазолу і його похідних та проміжні сполуки магнію
UA106386C2 (ru) Способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
CL2012003371A1 (es) Compuestos intermediarios de la síntesis de agomelatina; y el procedimiento de obtención de agomelatina a partir de dichos compuestos intermediarios
MX337997B (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
BRPI1016111A2 (pt) "método de produzir aço"
BR112012011786A2 (pt) "método para a produção de derivados de ácido glutâmico marcados por f-18"
MX2010003184A (es) Nuevo procedimiento de sinstesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
CL2012001081A1 (es) Procesos de preparcion de compuestos intermediarios en la sintesis de valsartan por hidrolisis de un ester utilizando salesde aluminio.
IT1394296B1 (it) Metodo di sintesi dell'acido glicocolico.
MX2011012233A (es) Soluciones de retinoide topicas.